L. Paz-Ares

913 total citations
51 papers, 374 citations indexed

About

L. Paz-Ares is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, L. Paz-Ares has authored 51 papers receiving a total of 374 indexed citations (citations by other indexed papers that have themselves been cited), including 45 papers in Oncology, 31 papers in Pulmonary and Respiratory Medicine and 8 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in L. Paz-Ares's work include Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Research Studies (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). L. Paz-Ares is often cited by papers focused on Lung Cancer Treatments and Mutations (26 papers), Lung Cancer Research Studies (21 papers) and Cancer Immunotherapy and Biomarkers (13 papers). L. Paz-Ares collaborates with scholars based in Spain, United States and France. L. Paz-Ares's co-authors include Fabrice Barlési, Emiliano Calvo, Josep Tabernero, Jean Tessier, Ali Tafreshi, Alex Martínez‐Martí, Solange Peters, Dolores Isla, Ernesto Guarin and Jean‐Philippe Spano and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

L. Paz-Ares

50 papers receiving 371 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
L. Paz-Ares Spain	9	291	215	97	40	38	51	374
Eisuke Kurihara Japan	8	148 0.5×	113 0.5×	110 1.1×	48 1.2×	32 0.8×	12	271
J.C.-H. Yang Taiwan	5	263 0.9×	281 1.3×	94 1.0×	46 1.1×	22 0.6×	12	353
M. D’Arcangelo Italy	12	200 0.7×	196 0.9×	119 1.2×	79 2.0×	30 0.8×	31	360
Jesper Andreas Palshof Denmark	9	246 0.8×	134 0.6×	99 1.0×	49 1.2×	34 0.9×	16	361
M.R. García Campelo Spain	9	284 1.0×	301 1.4×	119 1.2×	90 2.3×	32 0.8×	35	387
Daniela Iacono Italy	9	228 0.8×	266 1.2×	141 1.5×	64 1.6×	34 0.9×	19	372
Maria K. Hristova‐Kazmierski United States	5	258 0.9×	309 1.4×	103 1.1×	45 1.1×	18 0.5×	8	453
Umair Majeed United States	5	149 0.5×	159 0.7×	95 1.0×	81 2.0×	34 0.9×	27	295
Ajaz Bulbul United States	7	171 0.6×	206 1.0×	112 1.2×	75 1.9×	48 1.3×	20	348
Paul Swanson United States	7	212 0.7×	98 0.5×	141 1.5×	37 0.9×	49 1.3×	9	334

Countries citing papers authored by L. Paz-Ares

Since Specialization

Citations

This map shows the geographic impact of L. Paz-Ares's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by L. Paz-Ares with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites L. Paz-Ares more than expected).

Fields of papers citing papers by L. Paz-Ares

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by L. Paz-Ares. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by L. Paz-Ares. The network helps show where L. Paz-Ares may publish in the future.

Co-authorship network of co-authors of L. Paz-Ares

This figure shows the co-authorship network connecting the top 25 collaborators of L. Paz-Ares. A scholar is included among the top collaborators of L. Paz-Ares based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with L. Paz-Ares. L. Paz-Ares is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chiang, A. C., Jennifer W. Carlisle, Afshin Dowlati, et al.. (2025). Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy. ESMO Open. 10(4). 104538–104538. 4 indexed citations

Pascual, Tomás, Blanca González‐Farré, Fara Brasó‐Maristany, et al.. (2023). 2239P Gene expression profiling in tumors with and without tertiary lymphoid structures across cancer-types. Annals of Oncology. 34. S1153–S1154. 1 indexed citations

Jänne, Pasi A., Kiyotaka Yoh, SH Lee, et al.. (2023). 1319MO Intracranial efficacy of HER3-DXd in patients with previously treated advanced EGFR-mutated NSCLC: Results from HERTHENA-Lung01. Annals of Oncology. 34. S760–S761. 4 indexed citations

Besse, Benjamin, Libor Havel, Solange Peters, et al.. (2023). 120MO Adjuvant pembrolizumab versus placebo for early-stage NSCLC after resection and optional chemotherapy: Updated results from PEARLS/KEYNOTE-091. Immuno-Oncology Technology. 20. 100592–100592. 7 indexed citations

Griesinger, Frank, Egbert F. Smit, Rémi Veillon, et al.. (2022). 24P Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy. Annals of Oncology. 33. S40–S41. 2 indexed citations

Spira, Alexander I., Ranee Mehra, Charlene Mantia, et al.. (2022). 783TiP Phase I study of HFB301001, a novel OX40 agonist monoclonal antibody, in patients with solid tumors selected via Drug Intelligence Science (DIS). Annals of Oncology. 33. S899–S899. 2 indexed citations

Paz-Ares, L., E O’Brien, M. Mauer, et al.. (2022). VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study. Annals of Oncology. 33(4). 451–453. 49 indexed citations

Kowalski, Dariusz M., Alexander Luft, David Vicente Baz, et al.. (2022). 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Annals of Oncology. 33. S993–S994. 8 indexed citations

Peters, Solange, Sandrine Marréaud, Urania Dafni, et al.. (2022). 930MO PD-L1 expression and outcomes of pembrolizumab and placebo in completely resected stage IB-IIIA NSCLC: Subgroup analysis of PEARLS/KEYNOTE-091. Annals of Oncology. 33. S971–S972. 7 indexed citations

10.

Reck, Martin, et al.. (2022). 1026P Treatment switching adjustment of overall survival in the CheckMate 227 clinical trial of nivolumab plus ipilimumab versus chemotherapy in first-line treatment of patients with advanced non-small cell lung cancer. Annals of Oncology. 33. S1024–S1024. 1 indexed citations

11.

Paz-Ares, L., Fabrice Barlési, Salvatore Siena, et al.. (2021). Patient-reported outcomes from STARTRK-2: a global phase II basket study of entrectinib for ROS1 fusion-positive non-small-cell lung cancer and NTRK fusion-positive solid tumours. ESMO Open. 6(3). 100113–100113. 28 indexed citations

12.

Paz-Ares, L., Rafał Dziadziuszko, A. Drilon, et al.. (2019). MA14.02 Entrectinib in Patients with ROS1-Positive NSCLC or NTRK Fusion-Positive Solid Tumors with CNS Metastases. Journal of Thoracic Oncology. 14(10). S305–S305. 5 indexed citations

13.

Herbst, Roy S., Fabrice Barlési, L. Paz-Ares, et al.. (2019). P1.04-28 COAST: Durvalumab Alone or with Novel Agents for Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer. Journal of Thoracic Oncology. 14(10). S450–S451. 4 indexed citations

14.

Paz-Ares, L., David Planchard, James Chih‐Hsin Yang, et al.. (2018). MA26.10 CNS Activity of Ramucirumab in Combination with Osimertinib in Patients with Advanced T790M-Positive EGFR-Mutant NSCLC. Journal of Thoracic Oncology. 13(10). S453–S454. 2 indexed citations

15.

Paz-Ares, L., László Urbán, Clarisse Audigier-Valette, et al.. (2018). P1.01-79 CheckMate 817: Safety of Flat-Dose Nivolumab Plus Weight-Based Ipilimumab for the First-line (1L) Treatment of Advanced NSCLC. Journal of Thoracic Oncology. 13(10). S493–S493. 7 indexed citations

16.

Segal, Neil H., Ignacio Melero, Willeke Ros, et al.. (2017). Phase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC). Annals of Oncology. 28. v134–v134. 23 indexed citations

17.

Paz-Ares, L., Mark A. Socinski, Javad Shahidi, et al.. (2016). 1320_PR: Subgroup analyses of patients with epidermal growth factor receptor (EGFR)-expressing tumors in SQUIRE: A randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin (GC) plus necitumumab (N) versus GC alone in the first-line treatment of patients (pts) with stage IV squamous non-small cell lung cancer (sq-NSCLC). Journal of Thoracic Oncology. 11(4). S153–S153. 2 indexed citations

18.

Zimmer, Lisa, Fabrice Barlési, Maria Martinez‐García, et al.. (2014). Phase I Expansion and Pharmacodynamic Study of the Oral MEK Inhibitor RO4987655 (CH4987655) in Selected Patients with Advanced Cancer with RAS–RAF Mutations. Clinical Cancer Research. 20(16). 4251–4261. 59 indexed citations

19.

Santoro, Armando, Paolo Andrea Zucali, Mary O’Brien, et al.. (2007). Pemetrexed plus cisplatin (P plus CIS) or carboplatin (P plus CB) in chemonaive malignant pleural mesothelioma (MPM) patients (PTS): Results of the international expanded access program (EAP). Annals of Oncology. 18. 32–32. 1 indexed citations

20.

García, A., R. Pérez-Carrión, Pilar Garrido, et al.. (2007). Initial safety results of an open-label phase II trial of erlotinib in non-small cell lung carcinoma (NSCLC). Journal of Clinical Oncology. 25(18_suppl). 18038–18038.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact